126P - Assessment of EpCAM Intensity of Expression and Outcome in breast Carcinoma Neoadjuvant Chemotherapy Treated Patients

Date 18 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Anticancer Agents
Breast Cancer, Metastatic
Translational Research
Presenter AHMAD Shalaby
Citation Annals of Oncology (2016) 27 (suppl_9): ix35-ix41. 10.1093/annonc/mdw577
Authors A.M.R. Shalaby
  • Oncologic Pathology, Kameda Medical Center, 8602 - Kamogawa/JP



Back ground: The wide use of Neoadjuvant chemotherapy nowadays became so wide to the degree that it is more or less established as a standard regimen in management of breast neoplasia, in spite of different outcome results. Expression of epithelial cell adhesion molecule (EpCAM) is deregulated in epithelial malignancies. It is found that it acts as signaling molecule with tumor-promoting functions in addition to its role in cell adhesion. Aim of Work: It is aimed to assess the expression intensity of malignant mammary cells of EpCAM and its relation to the patient out come and their response to neoadjuvant chemotherapy.


140 patients with breast carcinoma and undergone treatment with neoadjuvant chemotherapy were included in the study. Both Tru-cut tissue biopsy and radically-excised breast tissues; before and after neoadjuvant chemotherapy, were examined for intensity of staining by EpCAM.


High intensity of EpCAM expression pattern is found correlated with lympho-vascular invasion status and higher nuclear grade (P = 0.01 and 0.008, respectively), and was associated with poor outcome (P 


Strong EpCAM intensity in carcinoma of breast is correlated with bad response to neoadjuvant chemotherapy and subsequently with worse prognosis than in patients with negative or low staining intensity.

Clinical trial indentification

Legal entity responsible for the study





All authors have declared no conflicts of interest.